2012 
2011 2010 2009 2008| 2011 |
Chutiwitoonchai N, Hiyoshi M, Mwimanzi P, Ueno T, Adachi A, Ode H, Sato H, Fackler OT, Okada S, and Suzu S. The identification of a small molecule compound that reduces HIV-1 Nef-mediated viral infectivity enhancement. PLoS One, 6(11):e27696, 2011 |
|
 |
|
Narumi, T., Arai, H.,Yoshimura, K.,Harada, S., Nomura, W., Matsushita, S., Tamamura. H. Small molecular CD4 mimics as HIV entry inhibitors. Bioorg Med Chem , 19: 6735-6742 (2011). |
|
|
|
Nishijima T, Tsukada K, Takeuchi S, Chiba A, Honda M, Teruya K, Gatanaga H, Kikuchi Y and Oka S, Antiretroviral Therapy for Treatment-naive Chronic HIV-1Infection with an Axonal Variant of Guillain-Barre Syndrome Positive for Anti-ganglioside Antibody: A Case Report. Intern Med 50: 2427-2429, 2011. |
|
|
|
Koito A, and Ikeda T. Intrinsic restriction activity by AID/APOBEC family of enzymes against the mobility of retroelements. Mobile Genet. Elements. 1(3): 197-202, 2011. |
|
|
|
| Watanabe K, Gatanaga H, Cadiz A, Tanuma J, Nozaki T, and Oka S, Amebiasis in HIV-infected Japanese men: Clinical features and response to therapy. PLoS Niglect Trop Dis 5: e1318, 2011. | |
|
|
| Hamada Y, Watanabe K, Aoki T, Arai N, Honda M, Kikuchi Y, Oka S, Primary HIV Infection with Acute Transverse Myelitis. Intern Med 50(15):1615-7, 2011. | |
|
|
| Iglesias MC, Almeida JR, Fastenackels S, Bockel DJ, Hashimoto M, Venturi V, Gostick E, Urrutia A, Wooldridge L, Clement M, Gras S, Wilmann PG, Autran B, Moris A, Rossjohn J, Davenport MP, Takiguchi M, Brander C, Douek DC, Kelleher AD, Price DA, and Appay V, Escape from highly effective public CD8+ T cell clonotypes by HIV. Blood 118: 2138-2149, 2011. | |
|
|
| Nishijima T, Tsukada K, Nataga, N, Watanabe K, Teruya K, Gatanaga H, Kikuchi Y, and Oka S, Antiretoriviral therapy alone resulted in successful resolution of large idiopathic esophageal ulcers in a patient with acute retroviral syndrome. AIDS (Correspondence) 25: 1677-1679, 2011. | |
|
|
Nishijima T, Komatsu H, Gatanaga H, Aoki T, Watanabe K, Kinai E, Honda H, Tanuma J, Yazaki H, Tsukada K, Honda M, Teruya K, Kikuchi Y and Oka S, Impact of small body weight on Tenofovir-associated renal dysfunction in HIV-infected patients: A retrospective cohort study of Japanese patients. PLoS One 6: e22661, 2011. |
|
|
|
Zhang Y, Peng Y, Yan H, Xu K, Saito M, Wu H, Chen X, Ranasinghe S, Kuse N, Powell T, Zhao Y, Li W, Zhang X, Feng X, Li N, Leligdowicz A, Xu X, John M, Takiguchi M, McMichael A, Rowland-Jones S, and Dong T. Multilayered Defense in HLA-B51-Associated HIV Viral Control. J. Immunol. 187:684-691, 2011 |
|
|
|
| Ikeda T, Abd El Galil KH, Tokunaga K, Maeda K, Sata T, Sakaguchi N, Heidmann T, and Koito A. Intrinsic restriction activity by apolipoprotein B mRNA editing enzyme APOBEC1 against the mobility of autonomous retrotransposons. Nucleic Acids Res. 39(13): 5538-5554, 2011 | |
|
|
| Mwimanzi P, Hasan Z, Hassan R, Suzu S, Takiguchi M, and Ueno T, Effects of naturally-arising HIV Nef mutations on cytotoxic T lymphocyte recognition and Nef’s functionality in primary macrophages. Retroviology 8:50, 2011 | |
|
|
| Yuan Y, Maeda Y, Terasawa H, Monde K, Harada S, and Yusa K, A combination of polymorphic mutations in V3 loop of HIV-1 gp120 can confer noncompetitive resistance to maraviroc. Virology 413: 293-299, 2011. | |
|
|
| Honda M, Ishisaka M, Ishizuka N, Kimura S, Oka S on behalf of Japanese Anti-HIV-1 QD Study Group. Open-label randomized multicenter selection study of once daily antiretroviral treatment regimen comparing ritonavir boosted atazanavir to efavirenz with fixed dose abacavir and lamivudine. Intern Med. 50:699-705, 2011 | |
|
|
| Ide K, Aoki M, Amano M, Koh Y, Yedidi RS, Das D, Leschenko S, Chapsal B, Ghosh AK, and Mitsuya H. Novel HIV-1 protease inhibitors (PIs) containing a bicyclic P2 functional moiety, tetrahydropyrano-tetrahydrofuran (Tp-THF), that are potent against multi-PI-resistant HIV-1 variants. Antimicrob Agnets Chemother. 55:1717-1727, 2011 | |
|
|
Ong EBB, Watanabe N, Saito A, Futamura Y, Abd El Galil KH, Koito A, Najimudin N, and Osada H. Vipirinin, a coumarin-based HIV-1 Vpr inhibitor, interacts with a hydrophobic region of Vpr. J. Biol. Chem. 286(16):14049-14056, 2011. |
|
|
|
| Davaalkham J, Unenchimeng P, Baigalmaa C, Erdenetuya G, Nyamkhuu D, Shiino T, Tsuchiya K, Hayashida T, Gatanaga H, and Oka S, Identification of a current hot spot of HIV-1 transmission in Mongolia by molecular epidemiological analysis. AIDS Res Hum Retrovisus 27: 1073-80, 2011 | |
|
|
| Goto H, Hagiwara S, Hirai R, Miyama T, Honda H, Tagashira A, Iizuka T, Mochizuki M, Teruya K, Kikuchi Y, Oka S, and Miwa A. Case of relapsed AIDS-related plasmablastic lymphoma treated with autologous stem cell transplantation and highly active antiretroviral therapy. Rare Tumors 3: 33-35, 2011. | |
|
|
Hachiya A, Kodama EN, Schuckmann MM, Kirby KA, Michailidis E, Sakagami Y, Oka S, Singh K, and Sarafianos SG, K70Q adds high-level tenofovir resistance to "Q151M complex" HIV reverse transcriptase through the enhanced discrimination mechanism. PLoS One 6, e16242, 2011. |
|
|
|
| Ishikawa N, Ishigaki K, Ghidinelli MN, Ikeda K, Honda M, Miyamoto H, Kakimoto K, and Oka S, Paediatric HIV and elimination of mother-to-child transmission of HIV in the ASEAN region: a call to action. AIDS Care 23: 413-416, 2011. | |
|
|
| Nagata N, Kobayashi M, Shimbo T, Hoshimoto K, Yada T, Gotoda T, Akiyama J, Oka S, and Uemura N, Diagnostic value of antigenemia assay for CMV gastrointestinal disease in immunocompromised patients. World J Gastroenterol 17: 1185-1191, 2011. | |
|
|
| Nakamura H, Teruya K, Takano M, Tsukada K, Tanuma J, Yazaki H, Honda H, Honda M, Gatanaga H, Kikuchi Y, and Oka S. Clinical symptoms and courses of primary HIV-1 infection in recent years in Japan. Intern Med. 50(2):95-101, 2011 | |
|
|
| Naruto T, Murakoshi H, Chikata T, Koyanagi M, Kawashima Y, Gatanaga H, Oka S, and Takiguchi M, Selection of HLA-B57-associated Gag A146P mutant by HLA-B*48:01-resticted Gag140-147-specific CTLs in chronically HIV-1-infected Japanese. Microbes and Infection 13: 766-770, 2011 | |
|
|
| Ghosh AK, Martyr CD, Steffey M, Wang YF, Agniswamy J, Amano M, Weber IT, and Mitsuya H. Design of substituted bis-tetrahydrofuran (bis-THF)-derived potent HIV-1 protease inhibitors, protein-ligand X-ray structure, and convenient syntheses of bis-THF and substituted bis-THF ligands. ACS Med Chem Lett. 2 (4): 298–302, 2011 | |
|
|
| Ghosh AK, Chapsal BD, Baldridge A, Steffey MP, Walters DE, Koh Y, Amano M, and Mitsuya H. Design and Synthesis of Potent HIV-1 Protease Inhibitors Incorporating Hexahydrofuropyranol-Derived High Affinity P(2) Ligands: Structure-Activity Studies and Biological Evaluation. J Med Chem. 54(2):622-634, 2011. | |
|
|
| Watanabe T, Murakoshi H, Gatanaga H, Koyanagi M, Oka S, and Takiguchi M. Effective recognition of HIV-1-infected cells by HIV-1 integrase-specific HLA-B*4002-restricted T cells. Microbes Infect. 13(2):160-166, 2011 | |
|
|
| Honda K, Zheng N, Murakoshi H, Hashimoto M, Sakai K, Borghan MA, Chikata T, Koyanagi M, Tamura Y, Gatanaga H, Oka S, and Takiguchi M. Selection of escape mutant by HLA-C-restricted HIV-1 Pol-specific cytotoxic T lymphocytes carrying strong ability to suppress HIV-1 replication. Eur J Immunol. 41(1):97-106, 2011. | |
|
|
| MaedaY, Yusa K, Nakano Y, and Harada S. Involvement of inhibitory factors in the inefficient entry of HIV-1 into the human CD4 positive HUT78 cell line. Virus Res. 155(1):368-371, 2011 | |
 |
 |